Exosomes · Lesson 9 of 18 · 3 min

What is exosome therapy?

A plain introduction to exosome therapy: what exosomes are, why researchers study them as a cell-free alternative to stem cells, and where regulation stands.

A gloved hand pipetting into small vials on a lab bench

Key takeaways.

  • Exosomes are extracellular vesicles, typically 30 to 150 nanometers across, released by cells.
  • Exosome therapy uses vesicles isolated from selected donor cells rather than the living cells themselves.
  • Most clinical development uses exosomes from mesenchymal stem cells (MSCs).
  • Exosomes are non-living and cannot replicate, which is the main safety argument made for them over cell therapy.
  • As of 2024, no exosome product has FDA approval for any indication. All therapeutic use is investigational.
  • Most registered therapeutic trials are still early phase, focused on safety and preliminary signals.

What exosome therapy means

Exosomes are small extracellular vesicles, meaning membrane-bound particles that cells release to signal to other cells. They typically measure 30 to 150 nanometers in diameter.

Exosome therapy is the administration of vesicles that have been isolated from selected donor cells. The idea came from stem cell research. Investigators came to think that much of the activity of mesenchymal stem cells (MSCs) comes from the factors they secrete, not from the cells turning into new tissue. Exosomes carry many of those factors.

Why researchers compare exosomes with cell therapy

The main argument is safety. Living stem cells can divide, so cell therapy carries a theoretical risk that transplanted cells could form tumors. Exosomes have no genome and cannot replicate, so the course material describes this specific risk as not applying to them.

This is a theoretical advantage. It does not mean exosome products are proven safe, and it says nothing about whether they provide clinical benefit.

Where exosomes come from

MSC-derived exosomes dominate current clinical development. MSCs were first identified in bone marrow and have since been isolated from many tissues.

Exosomes from different tissue sources have overlapping but distinct characteristics. Source selection therefore affects biology, manufacturing and the regulatory path.

Regulatory and clinical status

In the United States, the FDA regulates exosome products as biologics under Section 351 of the Public Health Service Act. Developers must show safety and efficacy in controlled trials, manufacture under good manufacturing practice, and obtain a Biologics License Application approval before marketing.

As of 2024, no exosome-based therapeutic product has received FDA approval for any indication. ClinicalTrials.gov lists over 200 trials involving exosomes as therapeutic agents or diagnostic biomarkers. Most therapeutic trials are Phase I or II.

Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.

Exosomes: 0 of 18 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • How MSC tissue sources compare in practice
  • Reading a product's characterization and quality data
  • How FDA rules apply to products marketed to clinics
  • The global trial landscape by indication

Common questions.

Are exosomes FDA-approved?
No. Exosome therapies are not FDA-approved for any therapeutic use. As of 2024, no exosome-based product has been approved for any indication, and all therapeutic applications remain investigational.
How is exosome therapy different from stem cell therapy?
Stem cell therapy administers living cells. Exosome therapy administers non-living vesicles isolated from cells, which carry some of the factors those cells secrete. Neither is FDA-approved for therapeutic use.
What cells are most exosome products derived from?
Most clinical development uses exosomes derived from mesenchymal stem cells, which can be isolated from bone marrow and several other tissues.

Sources

  • Phinney, D. G., & Pittenger, M. F. (2017). Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 35(4), 851-858.
  • Théry, C., et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles, 7(1), 1535750.
  • Kordelas, L., et al. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia, 28(4), 970-973.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.